Please ensure Javascript is enabled for purposes of website accessibility

Cronos Group: Buy the Dip?

By George Budwell - Updated Apr 16, 2019 at 10:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street has turned sour on Cronos' near-term outlook. Should everyday investors do the same?

Yesterday, Cronos Group (CRON -4.52%) fell by nearly 10% after a slew of downgrades from top firms like Canaccord Genuity. Analysts are reportedly turning bearish on the stock in response to the company's uninspiring 2018 fourth-quarter and full-year earnings release earlier this week. 

The short story is that Wall Street thinks investors are putting too much stock into Cronos' partnership with American tobacco giant Altria Group (MO -1.04%), especially since the company isn't well positioned in the Canadian adult-use market and international cannabis sales could take years to ramp up.

Stacks of jars containing dried marijuana buds.

Image source: Getty Images.

Are analysts missing the bigger picture with this mid-cap pot stock? Or should investors take these downgrades as a sign of things to come? Let's dig deeper to solve this riddle. 

Bulls vs. bears

Wall Street has a strong case against Cronos Group. The company sports one of the highest valuations within its immediate peer group, but also one of the lowest forward-looking production outputs.

Company Projected 2020 Price-to-Sales Ratio Estimated Peak Annual Production Capacity (kgs)
Aphria 5.3 255,000
Aurora Cannabis 13.4 700,000
Canopy Growth 14.8 > 500,000
Cronos Group 18.4 120,000
HEXO 3.4 150,000
Tilray 19.1 > 200,000

Cronos has been countering these criticisms by claiming that Wall Street simply isn't seeing the forest for the trees. In short, the company's core business strategy is to capitalize on key value-added areas in order to build a viable economic moat -- instead of competing on sheer production volume. 

Turning to the specifics, Cronos is banking on its partnership with Altria to maximize the efficiency of its supply chain. By doing so, the company's goal is to ratchet up its gross margins on value-added products like world-class pre-rolls and customized cannabis vaporizers. This move seems particularly wise, given that Altria has a proven track record at maximizing its supply chain, as well as building iconic brands like Marlboro.

Cronos' strategic decision to focus mainly on the end-user portion of the supply chain and to look toward international markets as the main growth opportunities could pay off big down the road. The downside to this approach, though, is that the step-wise fashion in which the legal U.S. cannabis space has evolved has led to a highly fragmented marketplace, as well as a messy legal landscape at the state level. Altria and Cronos thus have a lot of work to do to consolidate this high-value marketplace -- and an enormous amount of entrenched competition to overcome as well.  

Check out the latest earnings call transcripts for Cronos Group and Altria Group.

Is this dip a buying opportunity?

If you're buying shares of Cronos at these levels, you're gonna have to look toward what the company could become within the next few years, not what it is right now. After all, Cronos is a flat-out laggard in the Canadian cannabis space, with a bloated valuation to boot. But this imaginative approach toward investing is without question a risky proposition. 

While the U.S. is indeed starting to lead toward ending federal prohibition on cannabis, Altria and Cronos won't immediately cash in once this key market opens up. The duo will undoubtedly have to deal with numerous logistical and legal headwinds in differing jurisdictions, as each state overhauls its marijuana policies in accordance with the new law of the land. This process could take years to smooth out.

Viewed this way, Cronos' sharp pullback this week probably doesn't represent a great buying opportunity. Legal cannabis does present an impressive commercial opportunity, but most of this latent value will probably take several years to materialize.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
$3.38 (-4.52%) $0.16
Altria Group, Inc. Stock Quote
Altria Group, Inc.
$53.67 (-1.04%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.